J&J/Guidant update
This article was originally published in The Gray Sheet
Executive Summary
S-4 registration statement for planned merger declared effective by Securities & Exchange Commission, firms announce March 24. Guidant shareholders will meet in Indianapolis April 27 to vote on the proposal, still subject to approval by the Federal Trade Commission and European Union. The transaction will be completed in the third quarter, the companies estimate (1"The Gray Sheet" Dec. 20, 2004, p. 3)...
You may also be interested in...
J&J Claims Guidant For $23.9 Bil., Forms CV Device Group Under Valeriani
Johnson & Johnson's willingness to pay $24 bil. (6.5-times revenue) for Guidant validates the long-standing claim of ICD manufacturers that the cardiac rhythm management market is largely underserved
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.